青少年和年轻成人接种4CMenB疫苗后4年和7.5年的抗体持久性与加强应答
这项开放标签多中心研究评估了青少年/年轻成人接种4CMenB疫苗后4年和7.5年的杀菌抗体持久性及加强针应答。结果显示,除NHBA外,初免者抗体水平虽下降但仍高于未接种者;加强针或补种后93-100%初免者和79-100%未接种者hSBA滴度≥4,早期应答强烈,安全性良好。
要点
- 初免后4年和7.5年抗体下降,但除NHBA外仍高于未接种者。
- 加强针后93-100%初免者和79-100%未接种者hSBA滴度≥4。
- 加强针或第二剂后7天出现早期强烈抗体应答。
核心结论
- 除NHBA外,初免者在接种后4年和7.5年hSBA滴度≥4的比例高于未接种者。
- 加强针应答强于未接种者首剂,表明青少年/年轻成人初免有效。
- 未发现安全性或新的反应原性问题。
研究设计与样本
- 开放标签、多中心研究(NCT02446743),纳入15-24岁既往接种者(加拿大、澳大利亚4年组;智利7.5年组)和年龄匹配的未接种者。
- 初免者接种1剂加强针,未接种者接种2剂补种(间隔1个月)。
- 采用hSBA评估抗体持久性和免疫应答,报告几何平均滴度和hSBA滴度≥4的比例。
主要发现
- 初免后4年和7.5年抗体水平下降,但基线时hSBA滴度≥4的比例除NHBA外均高于未接种者:fHbp≤44% vs ≤13%,NadA≤84% vs ≤24%,PorA≤29% vs ≤14%,NHBA≤81% vs ≤79%。
- 加强针或第二剂后1个月,93-100%初免者和79-100%未接种者所有抗原hSBA滴度≥4。
- 各组抗体应答动力学相似,加强针/第二剂后7天观察到早期强烈应答。
- 未报告疫苗相关严重不良事件。
关键数值与推荐
- hSBA滴度≥4为保护性阈值。
- 初免后4年(Primed_4y)和7.5年(Primed_7.5y)抗体持久性数据。
- 加强针后1个月93-100%初免者hSBA滴度≥4。
- 未接种者2剂补种后1个月79-100%hSBA滴度≥4。
临床怎么用
- 青少年/年轻成人接种4CMenB后4-7.5年抗体虽下降但仍高于未接种者,支持初免效果持久。
- 加强针可诱导强烈回忆应答,支持在青少年/年轻成人中实施加强免疫。
- 未接种青少年/年轻成人补种2剂4CMenB可获良好免疫应答。
局限性
- 开放标签设计,未设盲。
- 初免队列来自不同国家,初免程序不完全相同。
- 未报告长期保护效力数据,仅以hSBA滴度替代。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Data on duration of protection against invasive meningococcal disease post-vaccination with the recombinant, 4-component, meningococcal serogroup B vaccine (4CMenB) are limited. We evaluated bactericidal activity persistence in adolescents/young adults up to 7.5 years post-primary vaccination with 4CMenB, and response to a booster dose compared with vaccine-naïve controls. METHODS: This open-label, multicenter study (NCT02446743) enrolled 15-24 year-old-previously vaccinated participants from Canada, Australia (group Primed_4y) 4 years post-priming with 4CMenB (2 doses; 0,1-month schedule), and Chile (Primed_7.5y) 7.5 years after priming with 4CMenB (2 doses; 0,1/0,2/0,6-month schedule) and vaccine-naïve participants of similar age (Naïve_4y and Naïve_7.5y groups). Primed participants received a booster dose; vaccine-naïve participants received 2 catch-up doses of 4CMenB, 1 month apart. We evaluated antibody persistence and immune responses using hSBA in terms of geometric mean titers and percentages of participants with hSBA titers ≥4, the kinetics of bactericidal activity post-booster (previously vaccinated) or post-2 doses (vaccine-naïve), and safety. RESULTS: Antibody levels declined at 4 (Primed_4y) and 7.5 (Primed_7.5y) years post-primary vaccination, but remained higher than in vaccine-naïve participants at baseline (≤44% vs ≤ 13% [fHbp]; ≤84% vs ≤ 24% [NadA]; ≤29% vs ≤ 14% [PorA]) for all vaccine antigens except NHBA (≤81% vs ≤ 79%). One month post-booster and post-second dose, 93-100% of primed and 79-100% of vaccine-naïve participants had hSBA titers ≥4 for all antigens. Kinetics of the antibody response were similar across groups with an early robust response observed 7 days post-booster/second dose. No vaccine-related serious adverse event was reported. CONCLUSION: For all antigens except NHBA, a higher proportion of primed participants had hSBA titers ≥4, at 4 and 7.5 years post-vaccination, compared with vaccine-naïve participants. A more robust immune response after booster compared to a first dose in vaccine-naïve individuals, showed effective priming in an adolescent/young adult population. No safety or new reactogenicity issues were identified.
引用
- Nolan T, Santolaya ME, de Looze F, et al. Antibody persistence and booster response in adolescents and young adults 4 and 7.5 years after immunization with 4CMenB vaccine. Vaccine. 2019. PMID: 30691980. doi:10.1016/j.vaccine.2018.12.059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。